medRxiv PreprintsInternational18 November 2026
Genetically Proxied NLRP3 Inflammasome Downregulation and Cardiovascular Disease
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Background: The inhibition of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is an emerging therapeutic strategy for atherosclerotic cardiovascular disease (ASCVD). Although early clinical trials demonstrate reductions in inflammatory biomarkers, whether these translate into cardiovascular benefit remains uncertain. We investigated the potential efficacy and safety of NLRP3 inhibition using human genetics. Methods: We developed a cis-genetic instrument for NLRP3 downregulation using C-reactive protein (CRP) associated variants (P<5 x 10^-8) within the NLRP3 locus (+/-100
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.